Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue 4, Pages 333-347
Publisher
Wiley
Online
2015-11-24
DOI
10.1111/dom.12610
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Combination of DPP-4 Inhibitors Versus Sulfonylureas with Metformin After Failure of First-line Treatment in the Risk for Major Cardiovascular Events and Death
- (2015) Oriana Hoi Yun Yu et al. Canadian Journal of Diabetes
- Treating Diabetes Mellitus in Older and Oldest Old Patients
- (2015) A.M. Abbatecola et al. CURRENT PHARMACEUTICAL DESIGN
- Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study
- (2015) P. Valensi et al. DIABETES & METABOLISM
- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
- (2015) Nikolaus Marx et al. Diabetes & Vascular Disease Research
- Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
- (2015) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension
- (2015) S.-M. Jin et al. DIABETES OBESITY & METABOLISM
- Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial
- (2015) B. Gallwitz et al. DIABETES OBESITY & METABOLISM
- Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study
- (2015) G. Leibowitz et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
- (2015) A. S. Abdelmoneim et al. DIABETES OBESITY & METABOLISM
- Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy
- (2015) S. E. Inzucchi et al. DIABETES OBESITY & METABOLISM
- Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality—A retrospective nationwide study
- (2015) Ulrik Madvig Mogensen et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
- (2015) Wolfgang Kothny et al. DIABETOLOGIA
- Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2015) Silvio E. Inzucchi et al. DIABETOLOGIA
- Evogliptin: First Global Approval
- (2015) Paul L. McCormack DRUGS
- Trelagliptin: First Global Approval
- (2015) Kate McKeage DRUGS
- Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial
- (2015) Paul Hartley et al. DRUGS & AGING
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
- (2015) Nobuya Inagaki et al. Lancet Diabetes & Endocrinology
- Mortality risk among sulfonylureas: a systematic review and network meta-analysis
- (2015) Scot H Simpson et al. Lancet Diabetes & Endocrinology
- Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
- (2015) Jong-Mi Seong et al. PLoS One
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
- (2014) Michael Lehrke et al. CLINICAL THERAPEUTICS
- Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk
- (2014) Elaine Chow et al. DIABETES
- Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
- (2014) Itamar Raz et al. DIABETES CARE
- Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes
- (2014) A. Avogaro et al. DIABETES OBESITY & METABOLISM
- Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study
- (2014) C. Ll. Morgan et al. DIABETES OBESITY & METABOLISM
- Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality
- (2014) C. Ll. Morgan et al. DIABETES OBESITY & METABOLISM
- A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes
- (2014) M. Monami et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
- (2014) T. M. E. Davis DIABETES OBESITY & METABOLISM
- Risk of pancreatitis in patients treated with incretin-based therapies
- (2014) Juris J. Meier et al. DIABETOLOGIA
- Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
- (2014) Tesfaye Biftu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
- (2014) Namyi Gu et al. Drug Design Development and Therapy
- Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
- (2014) Bo Ahrén et al. Diabetes Therapy
- Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
- (2014) Paul Craddy et al. Diabetes Therapy
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus
- (2013) Christianne L. Roumie et al. ANNALS OF INTERNAL MEDICINE
- A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
- (2013) Mika Nabeno et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "Isoglycemic" Intravenous Glucose
- (2013) I. Vardarli et al. DIABETES
- Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes
- (2013) Carolina Solis-Herrera et al. DIABETES CARE
- Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias
- (2013) A. Stahn et al. DIABETES CARE
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- (2013) D. M. Nathan et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2014
- (2013) DIABETES CARE
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
- (2013) E. J. Rhee et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
- (2013) Giuseppe Derosa et al. Diabetes Technology & Therapeutics
- Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
- (2013) Boaz Hirshberg et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis
- (2013) J. E. Schopman et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETIC MEDICINE
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
- (2013) Alan Garber et al. Endocrine Practice
- Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
- (2013) Carolyn F Deacon et al. EXPERT OPINION ON PHARMACOTHERAPY
- Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry
- (2013) A. K. Gitt et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans
- (2013) Yoshinobu Nakamaru et al. XENOBIOTICA
- Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans
- (2013) Namtae Kim et al. XENOBIOTICA
- Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
- (2013) Daniel A. Tatosian et al. Diabetes Therapy
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
- (2012) Tomohiro Yoshida et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Gemigliptin, a Dipeptidyl Peptidase-IV Inhibitor: A Crossover Drug–Drug Interaction Study in Healthy Male Korean Volunteers
- (2012) Yook-Hwan Noh et al. CLINICAL THERAPEUTICS
- Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA1cvalue
- (2012) Karl J. Krobot et al. CURRENT MEDICAL RESEARCH AND OPINION
- Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study
- (2012) B. Guerci et al. DIABETES & METABOLISM
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
- (2012) J. Hong et al. DIABETES CARE
- Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis
- (2012) K. Gooßen et al. DIABETES OBESITY & METABOLISM
- Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England
- (2012) A. J. Farmer et al. DIABETIC MEDICINE
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans
- (2012) Shinji Furuta et al. XENOBIOTICA
- Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor
- (2011) Noriyasu Kato et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Variations in tissue selectivity amongst insulin secretagogues: a systematic review
- (2011) A. S. Abdelmoneim et al. DIABETES OBESITY & METABOLISM
- Treating diabetes today: a matter of selectivity of sulphonylureas
- (2011) S. Seino et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Heterozygous ABCC8 mutations are a cause of MODY
- (2011) P. Bowman et al. DIABETOLOGIA
- Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study
- (2011) Tina Ken Schramm et al. EUROPEAN HEART JOURNAL
- KCNJ11 gene E23K variant and therapeutic response to sulfonylureas
- (2011) Martin Javorsky et al. European Journal of Internal Medicine
- Emergency Hospitalizations for Adverse Drug Events in Older Americans
- (2011) Daniel S. Budnitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Severe Hypoglycemia and Risks of Vascular Events and Death
- (2010) Sophia Zoungas et al. NEW ENGLAND JOURNAL OF MEDICINE
- -Cell-Mediated Signaling Predominates Over Direct -Cell Signaling in the Regulation of Glucagon Secretion in Humans
- (2009) B. A. Cooperberg et al. DIABETES CARE
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
- (2009) Raffaele Marfella et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator
- (2008) J. Aittoniemi et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Mechanisms Underlying Acute Protection From Cardiac Ischemia-Reperfusion Injury
- (2008) Elizabeth Murphy et al. PHYSIOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search